FDA Type A Minutes Clear Path for GTx-104 Resubmission as Grace Therapeutics Adopts Dual-Source Manufacturing
GRCE sits 26% above its 52-week low of $1.79 on light trading volume (0.4× avg).
Summary
FDA Type A meeting minutes confirm no clinical issues with GTx-104 and outline a clear resubmission path. A dual-source manufacturing strategy is underway to resolve facility-level concerns, lowering regulatory risk.
Key Events · Product Development and Regulatory · GRCE
-
FDA Minutes Confirm No Clinical Issues
The FDA's Type A meeting minutes confirm that the Complete Response Letter identified no clinical safety or efficacy deficiencies and did not request additional clinical data for GTx-104.
-
Dual-Source Manufacturing Strategy
To reduce reliance on a single source, the company is remediating its current contract manufacturer while transferring technology to a second, U.S.-based site, providing multiple paths to a compliant registration site.
-
Clear Path to NDA Resubmission
The company intends to address all CRL items—facility cGMP compliance, additional leachables data, and excipient toxicology risk assessments—and will resubmit once fully addressed, supported by either or both manufacturers.
-
Updated Corporate Presentation
An updated corporate presentation details the regulatory path forward, trial data, and commercial preparation for GTx-104.
Analysis · GRCE · Life Sciences
The official FDA Type A meeting minutes confirm that the Complete Response Letter for GTx-104 raised no clinical safety or efficacy issues and requires no additional clinical data. The agency's concerns center solely on manufacturing facility compliance and non-clinical studies. To address this, the company is pursuing a dual-source manufacturing strategy—remediating its current contract manufacturer while transferring technology to a second, U.S.-based site—thereby reducing single-source risk. This regulatory clarity and proactive manufacturing approach materially de-risk the resubmission, a critical step for a company with a going-concern warning and a market cap of only $37 million.
At the time of this filing, GRCE was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.